{"count": 7, "results": [{"_id": "36015255", "pmid": 36015255, "pmcid": "PMC9412892", "title": "Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study", "journal": "Pharmaceutics", "authors": ["Elsayed MMA", "Aboelez MO", "Mohamed MS", "Mahmoud RA", "El-Shenawy AA", "Mahmoud EA", "Al-Karmalawy AA", "Santali EY", "Alshehri S", "Elsadek MEM", "El Hamd MA", "Ramadan AEH"], "date": "2022-08-04T00:00:00Z", "doi": "10.3390/pharmaceutics14081629", "meta_date_publication": "2022 Aug 4", "meta_volume": "14", "meta_issue": "8", "meta_pages": "", "score": 50278.797, "text_hl": "Bilayer @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@ROS@@@/@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@AT@@@ tablets had a remarkable effect on decreasing the @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ profiles, slowing @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@, and lowering blood pressure to normal levels when compared to the control group.", "citations": {"NLM": "Elsayed MMA, Aboelez MO, Mohamed MS, Mahmoud RA, El-Shenawy AA, Mahmoud EA, Al-Karmalawy AA, Santali EY, Alshehri S, Elsadek MEM, El Hamd MA, Ramadan AEH. Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study Pharmaceutics. 2022 Aug 4;14(8):. PMID: 36015255", "BibTeX": "@article{36015255, title={Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study}, author={Elsayed MMA and Aboelez MO and Mohamed MS and Mahmoud RA and El-Shenawy AA and Mahmoud EA and Al-Karmalawy AA and Santali EY and Alshehri S and Elsadek MEM and El Hamd MA and Ramadan AEH}, journal={Pharmaceutics}, volume={14}, number={8}}"}}, {"_id": "33423413", "pmid": 33423413, "title": "Clinical evaluation of infantile hemangiomas treated with atenolol.", "journal": "Dermatol Online J", "authors": ["Ballona R", "Zevallos J", "Núñez J"], "date": "2020-12-15T00:00:00Z", "meta_date_publication": "2020 Dec 15", "meta_volume": "26", "meta_issue": "12", "meta_pages": "", "score": 50263.88, "text_hl": "A descriptive, observational case series study of 30 @SPECIES_9606 @@@patients@@@ between the ages one to 5 months with superficial, deep, or mixed @DISEASE_Hemangioma_capillary_infantile @DISEASE_MESH:C535860 @@@IH@@@ was conducted between January 2016 and December 2017. Oral @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ was administered using a single once daily dose of 1mg/kg, which was adjusted for @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@ each month. ", "citations": {"NLM": "Ballona R, Zevallos J, Núñez J. Clinical evaluation of infantile hemangiomas treated with atenolol. Dermatol Online J. 2020 Dec 15;26(12):. PMID: 33423413", "BibTeX": "@article{33423413, title={Clinical evaluation of infantile hemangiomas treated with atenolol.}, author={Ballona R and Zevallos J and Núñez J}, journal={Dermatol Online J}, volume={26}, number={12}}"}}, {"_id": "37251972", "pmid": 37251972, "pmcid": "PMC10213604", "title": "Resistance to Thyroid Hormone Beta in a Patient Born to a Mother With Undiagnosed Graves' Disease", "journal": "AACE Clin Case Rep", "authors": ["Seetharaman S", "Quintos JB", "Salas-Lucia F"], "date": "2023-02-17T00:00:00Z", "doi": "10.1016/j.aace.2023.02.003", "meta_date_publication": "2023 May-Jun", "meta_volume": "9", "meta_issue": "3", "meta_pages": "63-66", "score": 50237.93, "text_hl": "The newborn had @DISEASE_Tachycardia @DISEASE_MESH:D013610 @@@tachycardia@@@ and delayed growth and was treated with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and supplemental feeding, resulting in @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@ and reduced heart rate.", "citations": {"NLM": "Seetharaman S, Quintos JB, Salas-Lucia F. Resistance to Thyroid Hormone Beta in a Patient Born to a Mother With Undiagnosed Graves' Disease AACE Clin Case Rep. 2023 May-Jun;9(3):63-66. PMID: 37251972", "BibTeX": "@article{37251972, title={Resistance to Thyroid Hormone Beta in a Patient Born to a Mother With Undiagnosed Graves' Disease}, author={Seetharaman S and Quintos JB and Salas-Lucia F}, journal={AACE Clin Case Rep}, volume={9}, number={3}, pages={63-66}}"}}, {"_id": "19574961", "pmid": 19574961, "title": "Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.", "journal": "Am J Hypertens", "authors": ["Zhang JL", "Zheng X", "Zou DJ", "Qiu JL", "Zhao XX", "Qin YW"], "date": "2009-08-01T00:00:00Z", "doi": "10.1038/ajh.2009.93", "meta_date_publication": "2009 Aug", "meta_volume": "22", "meta_issue": "8", "meta_pages": "884-90", "score": 50067.316, "text_hl": "@CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@Metformin@@@ may prevent @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@BW gain@@@ and improve @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@BG@@@ levels in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ who received combination therapy of @CHEMICAL_Nitrendipine @CHEMICAL_MESH:D009568 @@@nitrendipine@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@.", "citations": {"NLM": "Zhang JL, Zheng X, Zou DJ, Qiu JL, Zhao XX, Qin YW. Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. Am J Hypertens. 2009 Aug;22(8):884-90. PMID: 19574961", "BibTeX": "@article{19574961, title={Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.}, author={Zhang JL and Zheng X and Zou DJ and Qiu JL and Zhao XX and Qin YW}, journal={Am J Hypertens}, volume={22}, number={8}, pages={884-90}}"}}, {"_id": "3516792", "pmid": 3516792, "title": "Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.", "journal": "Gen Pharmacol", "authors": ["Bailey CJ", "Thornburn CC", "Flatt PR"], "date": "1986-01-01T00:00:00Z", "doi": "10.1016/0306-3623(86)90147-3", "meta_date_publication": "1986", "meta_volume": "17", "meta_issue": "2", "meta_pages": "243-6", "score": 50049.883, "text_hl": "Excessive @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@ in @GENE_LEP @GENE_16846 @@@ob@@@/@GENE_LEP @GENE_16846 @@@ob@@@ @SPECIES_10090 @@@mice@@@ was reduced (15-20%) by @CHEMICAL_Ephedrine @CHEMICAL_MESH:D004809 @@@ephedrine@@@, exacerbated (8-10%) by @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, but not significantly altered by a combination of these agents. ", "citations": {"NLM": "Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. Gen Pharmacol. 1986;17(2):243-6. PMID: 3516792", "BibTeX": "@article{3516792, title={Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.}, author={Bailey CJ and Thornburn CC and Flatt PR}, journal={Gen Pharmacol}, volume={17}, number={2}, pages={243-6}}"}}, {"_id": "16362700", "pmid": 16362700, "pmcid": "PMC3452015", "title": "Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up", "journal": "J Headache Pain", "authors": ["Maggioni F", "Ruffatti S", "Dainese F", "Mainardi F", "Zanchin G"], "date": "2005-09-01T00:00:00Z", "doi": "10.1007/s10194-005-0221-y", "meta_date_publication": "2005 Sep", "meta_volume": "6", "meta_issue": "4", "meta_pages": "322-4", "score": 50049.28, "text_hl": "After 6 months of therapy, the percentage of @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@ was 86% with @CHEMICAL_Pizotyline @CHEMICAL_MESH:D010918 @@@pizotifen@@@ (6/7; mean weight increase 4.4+-2.5 kg), 60% with @CHEMICAL_Amitriptyline @CHEMICAL_MESH:D000639 @@@amitriptyline@@@ 20 mg (6/10; 3.1+-1.6), 47% with @CHEMICAL_Amitriptyline @CHEMICAL_MESH:D000639 @@@amitriptyline@@@ 40 mg (9/19; 5.4+-2.7), 25% with @CHEMICAL_Valproic_Acid @CHEMICAL_MESH:D014635 @@@valproate@@@ 600 mg (2/8, 3.0+-2.8 kg), 25% with @CHEMICAL_Verapamil @CHEMICAL_MESH:D014700 @@@verapamil@@@ (1/4, 2.5 kg), 20% with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ (3/15, 1.7+-0.6 kg), 9% with @CHEMICAL_Gabapentin @CHEMICAL_MESH:D000077206 @@@gabapentin@@@ (1/11, 1.5 kg) and 8% with @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ (1/13; 6 kg). ", "citations": {"NLM": "Maggioni F, Ruffatti S, Dainese F, Mainardi F, Zanchin G. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up J Headache Pain. 2005 Sep;6(4):322-4. PMID: 16362700", "BibTeX": "@article{16362700, title={Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up}, author={Maggioni F and Ruffatti S and Dainese F and Mainardi F and Zanchin G}, journal={J Headache Pain}, volume={6}, number={4}, pages={322-4}}"}}, {"_id": "30289609", "pmid": 30289609, "pmcid": "PMC6220865", "title": "Insights on beta-blockers for the treatment of hypertension: A survey of health care practitioners", "journal": "J Clin Hypertens (Greenwich)", "authors": ["Egan B", "Flack J", "Patel M", "Lombera S"], "date": "2018-10-01T00:00:00Z", "doi": "10.1111/jch.13375", "meta_date_publication": "2018 Oct", "meta_volume": "20", "meta_issue": "10", "meta_pages": "1464-1472", "score": 50036.28, "text_hl": "First, physicians cited @DISEASE_Fatigue @DISEASE_MESH:D005221 @@@fatigue@@@ as the main reason for not using beta-blockers, a common reason for study discontinuation in clinical trials of early-generation beta-blockers such as @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@, @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, or timolol.6, 21 However, recent clinical evidence suggests that @DISEASE_Fatigue @DISEASE_MESH:D005221 @@@fatigue@@@ and other beta-blocker side effects are drug-specific rather than a class-wide effect.12, 14, 32 Second, physicians were split on their awareness of beta-blockers' impact on @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@: Surveyed physicians either associated all queried beta-blockers with @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@, were unaware that beta-blockers affect @<m>DISEASE_Weight_Gain</m> @DISEASE_MESH:D015430 @@@weight gain@@@, or associated only certain beta-blockers:@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ in particular:with these effects. ", "citations": {"NLM": "Egan B, Flack J, Patel M, Lombera S. Insights on beta-blockers for the treatment of hypertension: A survey of health care practitioners J Clin Hypertens (Greenwich). 2018 Oct;20(10):1464-1472. PMID: 30289609", "BibTeX": "@article{30289609, title={Insights on beta-blockers for the treatment of hypertension: A survey of health care practitioners}, author={Egan B and Flack J and Patel M and Lombera S}, journal={J Clin Hypertens (Greenwich)}, volume={20}, number={10}, pages={1464-1472}}"}}]}